Table 3. Subgroup analysis comparing AC versus AR following radical hysterectomy for recurrence.

Characteristics		Number of studies	AC patients (No.)	AR patients (No.)	OR (95% CI) for recurrence	p value	Study heterogeneity
							I2	p value, Cochran Q
Study design
	RCT	2	72	69	1.20 (0.53–2.70)	0.66	0%	0.35
	NRS	11	870	1,652	0.83 (0.63–1.09)	0.18	27%	0.06
Histology type
	SCC	3	183	202	0.51 (0.09–3.01)	0.46	83%	0.02
	ADC	2	86	92	0.42 (0.17–1.06)	0.07	34%	0.22
	All	8	673	1,337	1.06 (0.85–1.32)	0.60	0%	0.62
Indications for adjuvant treatment
	High-risk	4	510	1,045	0.93 (0.67–1.30)	0.69	31%	0.32
	Intermediate-risk	2	103	110	2.13 (0.45–10.01)	0.34	25%	0.25
	High- or intermediate-risk	5	179	376	0.63 (0.30–1.30)	0.21	52%	0.06
AR details
	CCRT	4	506	821	1.04 (0.81–1.35)	0.74	0%	0.37
	RT	7	350	465	0.82 (0.55–1.23)	0.33	19%	0.10
	CCRT or RT	2	86	182	0.54 (0.29–1.01)	0.054	0%	0.72
AC details
	Platinum combination with taxane only	2	97	117	1.45 (0.16–12.93).	0.74	70%	0.07
	Platinum combination with non-taxane only	5	280	374	0.84 (0.46–1.53)	0.57	49%	0.04
	Mixed	6	565	1,230	0.87 (0.62–1.21)	0.40	24%	0.41
Status of LNM
	LNM	3	473	971	0.94 (0.64–1.40)	0.77	45%	0.19
	No LNM	2	103	110	2.13 (0.45–10.01)	0.34	25%	0.25
	Mixed	6	216	450	0.72 (0.44–1.20)	0.21	27%	0.10

AC, adjuvant chemotherapy; ADC, adenocarcinoma; AR, adjuvant radiotherapy; CCRT, concurrent chemoradiotherapy; CI, confidence interval; LNM, lymph node metastasis; NRS, non-randomized study; OR, odds ratio; RCT, Randomized controlled trial; RT, radiotherapy; SCC, squamous cell carcinoma.